Entering text into the input field will update the search result below

Greenwich stock rises 14% as FDA lifts hold on phase 3 breast cancer trial

Jul. 12, 2022 6:32 AM ETGreenwich LifeSciences, Inc. (GLSI) StockBy: Ravikash Bakolia, SA News Editor

Headquarters of US Food and Drug Administration (FDA)

Grandbrothers

  • Greenwich LifeSciences (NASDAQ:GLSI) said the U.S. Food and Drug Administration (FDA) removed a clinical hold on a phase 3 trial in breast cancer allowing it to progress.
  • The trial, dubbed Flamingo-01, will evaluate a combination of immunotherapy GP2 + GM-CSF, together called

Recommended For You

More Trending News

About GLSI Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
GLSI--
Greenwich LifeSciences, Inc.